Cognitive and disease-modifying effects of 11β-hydroxysteroid dehydrogenase type 1 inhibition in male Tg2576 mice, a model of Alzheimer's disease

Endocrinology

Volumn 156, Issue 12, 2015, Pages 4592-4603

  Sooy, Karen ^a   Noble, June ^a   McBride, Andrew ^a   Binnie, Margaret ^a   Yau, Joyce L W ^a,b   Seckl, Jonathan R ^a,b   Walker, Brian R ^a   Webster, Scott P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; 4 (2 CHLOROPHENYL 4 FLUORO 1 PIPERIDINYL)[5 (1H PYRAZOL 4 YL) 3 THIENYL]METHANONE; ADAM10 ENDOPEPTIDASE; AMYLOID BETA PROTEIN; BETA SECRETASE 1; BETA TUBULIN; CD31 ANTIGEN; GLUCOCORTICOID; IBA PROTEIN; IDE PROTEIN; INSULINASE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; OXIDOREDUCTASE INHIBITOR; PEPTIDES AND PROTEINS; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPTOPHYSIN; THIOPHENE DERIVATIVE; UE 1961; UNCLASSIFIED DRUG; (4-(2-CHLOROPHENYL-4-FLUORO-1-PIPERIDINYL)(5-(1H-PYRAZOL-4-YL)-3-THIENYL)METHANONE; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; PYRAZOLE DERIVATIVE;

AGE; AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM; COGNITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; EMBRYO; EVIDENCE BASED PRACTICE; EXPERIMENTAL COGNITIVE DEFECT; FEMALE; HUMAN; HUMAN CELL; JUVENILE ANIMAL; LONG TERM CARE; MALE; MEMORY; MEMORY DISORDER; MOUSE; NEUROPATHOLOGY; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SHORT COURSE THERAPY; SINGLE DRUG DOSE; STRAIN DIFFERENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; MAZE TEST; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; COGNITION; DISEASE MODELS, ANIMAL; HUMANS; INSULYSIN; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, AMYLOID; PYRAZOLES; THIOPHENES;

EID: 84948169917     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1395     Document Type: Article

References (41)

1. Lupien SJ, de Leon M, de Santi S, et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci. 1998;1:69-73.
2. Starkman MN, Giordani B, Gebarski SS, Berent S, Schork MA, Schteingart DE. Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing's disease. Biol Psychiatry. 1999;46:1595-1602.
3. MacLullich AM, Deary IJ, Starr JM, Ferguson KJ, Wardlaw JM, Seckl JR. Plasma cortisol levels, brain volumes and cognition in healthy elderly men. Psychoneuroendocrinology. 2005;30:505-515.
4. de Kloet ER, Joëls M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci. 2005;6:463-475.
5. Woolley CS, Gould E, McEwen BS. Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons. Brain Res. 1990;531:225-231.
6. Lupien, SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behavior and cognition. Nat Rev Neurosci. 2009;10:434-445.
7. Reynolds RM. Glucocorticoid excess and the developmental origins of disease: two decades of testing the hypothesis. Psychoneuroendocrinology. 2013;38:1-11.
8. Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA. Increased CSF cortisol in AD is a function of APOE genotype. Neurology. 2001;56:1094-1098.
9. Cernansky JG, Dong H, Fagan AM, et al. Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia.AmJ Psychiatry. 2006;163:2164-2169.
10. Green KN, Billings LM, Roozendaal B, McGaugh JL, LaFerla FM. Glucocorticoids increase amyloid-β and τ pathology in a mouse model of Alzheimer's disease. J Neurosci. 2006;26:9047-9056.
11. Wang Y, Li M, Tang J, et al. Glucocorticoids facilitate astrocytic amyloid-β peptide deposition by increasing the expression of APP and BACE1 and decreasing the expression of amyloid-β-degrading proteases. Endocrinology. 2011;152:2704-2705.
12. Chapman KE, Holmes MC, Seckl JR. 11β-hydroxysteroid dehydrogenases: intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev. 2013;93:1139-1206.
13. Holmes MC, Carter RN, Noble J, et al. 11β-Hydroxysteroid dehydrogenase type 1 expression is increased in the aged mouse hippocampus and parietal cortex and causes memory impairments. J Neurosci. 2010;30:6916-6920.
14. Yau JL, Noble J, Kenyon CJ, et al. Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad Sci USA. 2001;98:4716-4721.
15. Sooy K, Webster SP, Noble J, et al. Partial deficiency or short term inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves cognitive function in aging mice. J Neurosci. 2010;30:13867-13872.
16. Mohler EG, Browman KE, Roderwald VA, et al. Acute inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves memory in rodent models of cognition. J Neurosci. 2011;31:5406-5413.
17. Yau JLW, Wheelan N, Noble J, et al. Intrahippocampal glucocorticoids generated by 11β-HSD1 affect memory in aged mice. Neurobiol Aging. 2014;36:334-343.
18. Sandeep TC, Yau JL, MacLullich AM, et al. 11β-Hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA. 2004; 101:6734-6739.
19. Sarabdjitsingh RA, Zhou M, Yau JLW, et al. Inhibiting 11β-hydroxysteroid dehydrogenase type 1 prevents stress effects on hippocampal synaptic plasticity and impairs contextual fear conditioning. Neuropharmacology. 2014;81:231-236.
20. Cobice F, Mackay CL, Goodwin RJ, et al. Mass spectrometry imaging for dissecting steroid intracrinology within target tissues. Anal Chem. 2013;85:11576-11584.
21. Webster SP, Seckl JR, Walker BR, et al. (4-Phenyl-piperidin-1-yl)- [5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use. Int PCT Application. 2011;WO2011033255.
22. Webster SP, Ward P, Binnie M, et al. Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors. Bioorg Med Chem Lett. 2007;17:2838-2843.
23. Yau JL, Noble J, Seckl JR. 11β-Hydroxysteroid dehydrogenase type 1 deficient prevents memory deficits with aging by switching from glucocorticoid receptor to mineralocorticoid receptor-mediated cognitive control. J Neurosci. 2011;31:4188-4193.
24. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99-102.
25. Yau JL, McNair KM, Noble J, et al. Enhanced hippocampal longterm potentiation and spatial learning in aged 11β-hydroxysteroid dehydrogenase type 1 knockout mice. J Neurosci. 2007;27:10487-10496.
26. Gil-Bea FJ, Aisa B, Schliebs R, Ramirez MJ. Increase of locomotor activity underlying the behavioral disinhibition in Tg2576 mice. Behav Neurosci. 2007;131:340-344.
27. Ishii M, Wang G, Racchumi G, Dyke JP, Iadecola C. Transgenic mice overexpressing amyloid precursor protein exhibit early metabolic deficits and a pathologically low leptin state associated with hypothalamic dysfunction in arcuate neuropeptide Y neurons. J Neurosci. 2014;34:9096-9106.
28. Thakker DR, Weatherspoon MR, Harrison J, et al. Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci USA. 2009;106:4501-4506.
29. Donmez G, Wang D, Cohen DE, Guarante L. SIRT1 suppresses β-amyloid production by activating the β-secretase gene ADAM10. Cell. 2010;142:320-332.
30. Calkins MJ, Manczak M, Mao P, Shirindeb U, Reddy PR. Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Human Mol Genet. 2011; 20:4515-4529.
31. McClean PL, Parthsarthy V, Faivre E, Hölscher C. The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J Neurosci. 2011;31:6587-6594.
32. Willuweit A, Velden J, Godemann R, et al. Early-onset and robust amyloid pathology in a new homozygous mouse model of Alzheimer's disease. PLoS One. 2009;4:e7931.
33. Small GR, Hadoke PWF, Sharif I, et al. Preventing local regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase type 1 enhances angiogenesis. Proc Natl Acad Sci USA. 2005;102:12165-12170.
34. Chen Y, Rex CS, Rice CJ, et al. Correlated memory defects and hippocampal dendritic spine loss after acute stress involve corticotropin- releasing hormone signalling. Proc Natl Acad Sci USA. 2010; 107:13123-13128.
35. Conrad CD, LeDoux JE, Magarinos AM, McEwen BS. Repeated restraint stress facilitates fear conditioning independently of causing hippocampal CA3 dendritic atrophy. Behav Neurosci. 1999;113: 902-913.
36. Leissring MA, Farris W, Chang AY, et al. Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40:1087-1093.
37. Farris W, Mansourian S, Chang Y, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β protein, and the beta amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA. 2003;100:4162-4167.
38. Vepsalainen S, Helisalmi S, Mannermaa A, Pirttila T, Soininen H, Hiltunen M. Combined risk effects of IDE andNEPgene variants on Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80:1268-1270.
39. Marek GJ, Katz DA, Meier A, et al. Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's disease. Alzheimers Dement. 2014;10:S364-S373.
40. Katz DA, Liu W, Locke C, et al. Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384. Transl Psychiatry. 2013;3:1-7.
41. Andrew R, Smith K, Jones GC, Walker BR. Distinguishing the activities of 11β-hydroxysteroid dehydrogenases in vivo using isotopically labelled cortisol. J Clin Endorinol Metab. 2002;87:277-285.